mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
6e-08 |
mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
4e-07 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
1e-06 |
mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
1e-06 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
4e-06 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
4e-06 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
5e-06 |
mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
2e-05 |
mRNA |
LRRK2-IN-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
2e-05 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
0.22 |
3e-05 |